Laurion Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Laurion Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-98,896	Closed	-$1.81M	–	270
2024 Q4	$1.81M	Buy	+98,896	New	+$1.6M	0.03%	187
2020 Q4	–	Sell	-23,200	Closed	-$957K	–	606
2020 Q3	$957K	Sell	23,200 -12,527	-35%	-$541K	0.01%	461
2020 Q2	$1.73M	Buy	+35,727	New	+$1.72M	0.02%	338
2019 Q4	–	Sell	-30,600	Closed	-$1.1M	–	854
2019 Q3	$1.1M	Buy	+30,600	New	+$928K	0.01%	626
2017 Q2	–	Sell	-9,664	Closed	-$332K	–	1596
2017 Q1	$332K	Buy	+9,664	New	+$341K	﹤0.01%	1044
2016 Q3	–	Sell	-112,100	Closed	-$3.64M	–	884
2016 Q2	$3.64M	Buy	+112,100	New	+$3.75M	0.06%	318
2015 Q3	–	Sell	-7,385	Closed	-$309K	–	717
2015 Q2	$309K	Buy	+7,385	New	+$286K	﹤0.01%	523
2014 Q2	–	Sell	-8,300	Closed	-$202K	–	279
2014 Q1	$202K	Buy	+8,300	New	+$210K	0.01%	220

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Laurion Capital Management's ACAD Position: Q1 2025 in Review

Laurion Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 98,896 shares — an estimated $1.81M sold.

Laurion Capital Management first reported a position in ACAD in Q1 2014 and held it in 8 quarters. The position peaked at $3.64M in Q2 2016. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Laurion Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Laurion Capital Management sold 98,896 Acadia Pharmaceuticals shares in Q1 2025, an estimated $1.81M.
Laurion Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Laurion Capital Management's Acadia Pharmaceuticals position peaked at $3.64M in Q2 2016.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Laurion Capital Management's 13F filing for Q1 2025, filed 15 May 2025.